At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 100 participants.
Detailed Summary
The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Taiwan.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedNov 2015
Primary CompletionNov 2017
TodayJul 2026
First PostedNov 26, 2015
Enrollment StartNov 5, 2015
Primary CompletionNov 23, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.6 years ago